At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 125 enrolled
Drug / intervention
LEO 80185 geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
In Brief
A Phase 2 clinical trial evaluating LEO 80185 gel for Psoriasis Vulgaris. Completed, enrolled 125 participants across 35 sites in 7 countries.
Detailed Summary
An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesCanada, France, Germany, Poland, Romania, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedJan 2014
Primary CompletionFeb 2018
Study CompletionFeb 2018
TodayJul 2026
First PostedJan 16, 2014
Enrollment StartJan 1, 2014
Primary CompletionFeb 1, 2018
Study CompletionFeb 13, 2018
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.5 years ago
Interventions
LEO 80185 geldrug